readthroughSign in
Nov 10, 2026Quarterly update

Alto Neuroscience reports Q3 2026 results, PACE-1 trial on track for TRD drug

Alto said its three-trial ALTO-207 program for treatment-resistant depression continues to advance, with a $100 million financing extending its cash runway through 2030.

Alto Neuroscience, Inc. reported financial results for the quarter ended September 30, 2026, on November 10, 2026. The PACE-1 Phase 2b trial, which targets approximately 178 adults with treatment-resistant depression (TRD), remains on enrollment track, with topline data expected in the second half of 2027.1

PACE-2, a Phase 3 adjunctive TRD trial, is expected to begin in early 2027 pending alignment with the FDA on trial design, and is planned to run in parallel with PACE-1 to speed a potential NDA submission.1 In July 2026, Alto announced plans to add PACE-3, a Phase 3 monotherapy TRD trial, which the company said could support a broader label; initiation is expected in the second half of 2027, pending FDA alignment.1

Alto recently completed a Phase 1 study of the pharmacokinetics and tolerability of its modified-release ALTO-207 formulation, the same formulation used in PACE-1 and planned for Phase 3 trials; together with blinded PACE-1 safety data, this is intended to inform final dose selection, with results expected in late 2026 or early 2027 following FDA feedback.1

Enrollment continues in separate Phase 2b trials of ALTO-300 in major depressive disorder and ALTO-100 in bipolar depression, with topline data expected in the first half of 2027 for ALTO-300 and mid-2027 for ALTO-100.1

In July 2026, Alto completed a registered direct offering of 3,776,436 shares at $26.48 per share, raising gross proceeds of $100.0 million, intended to accelerate and expand ALTO-207 development including PACE-3.1

As of September 30, 2026, Alto held cash, cash equivalents, and restricted cash of approximately $319.8 million, up from $177.0 million at the end of 2025, which the company said is expected to fund planned operations through 2030.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.